These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 14603670)

  • 1. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 2. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K
    Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract]   [Full Text] [Related]  

  • 3. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CHARM programme.
    Mansour J; Peltier M; Oprisiu R; Achard JM; Fournier A
    Lancet; 2003 Nov; 362(9396):1676-7; author reply 1678-9. PubMed ID: 14630455
    [No Abstract]   [Full Text] [Related]  

  • 5. [CHARM].
    Momomura S
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH; Kowalczykowski M; Hollar D
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
    McMurray JJ
    Heart; 2001 Jul; 86(1):97-103. PubMed ID: 11410575
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS
    J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conclusions from CHARM interview with Prof. Veselin Mitrovich, Bad Nauheim. Strong evidence: more help for weak hearts].
    Mitrovic V
    MMW Fortschr Med; 2005 Mar; 147(13):48-9. PubMed ID: 15832762
    [No Abstract]   [Full Text] [Related]  

  • 12. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    Swedberg K; McMurray JJ
    Eur Heart J; 2004 Mar; 25(5):357-8. PubMed ID: 15033244
    [No Abstract]   [Full Text] [Related]  

  • 15. The CHARM program: study design leads to findings of clinical and public health importance.
    Hennekens CH; Pfeffer MA; Swedberg K
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):124-6. PubMed ID: 17562782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [AT 1-blocker can be given in addition to ACE inhibitor and beta blocker. "Triple therapy decidedly well tolerated even in severe heart failure"].
    Dietz R
    MMW Fortschr Med; 2004 May; 146(22):50. PubMed ID: 15373115
    [No Abstract]   [Full Text] [Related]  

  • 17. Valsartan in chronic heart failure.
    Haddy FJ
    N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11948282
    [No Abstract]   [Full Text] [Related]  

  • 18. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
    Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Kudo Y; Komuro I; Akazawa H
    Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
    [No Abstract]   [Full Text] [Related]  

  • 20. Candesartan and heart failure: the allure of CHARM.
    White HD
    Lancet; 2003 Sep; 362(9386):754-5. PubMed ID: 13678864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.